Advertisement

Tumor Biology

, Volume 33, Issue 5, pp 1505–1510 | Cite as

RETRACTED ARTICLE: A translocator protein ligand PK11195 shows antigrowth activity in human choriocarcinoma cells

  • Noriyuki Takai
  • Naoko Kira
  • Terukazu Ishii
  • Toshie Yoshida
  • Masakazu Nishida
  • Yoshihiro Nishida
  • Kaei Nasu
  • Masayuki Takano
  • Haruna Midori
  • Satoko Koga
  • Hisashi Narahara
Research Article

Abstract

The potential anticancer agent 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195), a translocator protein ligand (initially described as a ligand for the peripheral benzodiazepine receptor), induces apoptosis in some lines of human tumor cells. We investigated the effect of PK11195 in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of PK11195, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A WST-1 assay showed that BeWo cells were sensitive to the growth inhibitory effect of PK11195. In contrast, the nonsite selective ligand diazepam has a little effect on these cells. Cell cycle analysis indicated that exposure to PK11195 decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine, by the loss of mitochondrial transmembrane potential, and by antibodies directed against histones from fragmented DNA. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that PK11195 may serve as a therapeutic agent for the treatment of choriocarcinoma.

Keywords

Translocator protein ligand PK11195 Cell cycle Apoptosis Choriocarcinoma 

Notes

Acknowledgments

This study was supported by a Grant-in-Aid (No. 21592139 to NT) for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan and by a Research Fund at the Discretion of the President, Oita University (HN).

Conflicts of interest

None.

References

  1. 1.
    Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease—the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565–70.PubMedGoogle Scholar
  4. 4.
    Decaudin D, Castedo M, Nemati F, et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 2002;62:1388–93.PubMedGoogle Scholar
  5. 5.
    Maaser K, Höpfner M, Jansen A, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001;85:1771–80.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sutter AP, Maaser K, Höpfner M, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer. 2002;102:318–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Le Fur G, Perrier ML, Vaucher N. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 1083;32:1839–47.CrossRefGoogle Scholar
  8. 8.
    Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Gonzalez-Polo RA, Carvalho G, Braun T, et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepine receptor. Oncogene. 2005;24:7503–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med. 1997;186:25–37.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zoratti M, Szabò I. The mitochondrial permeability transition. Biochim Biophys Acta. 1995;1241:139–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003;8:115–28.CrossRefPubMedGoogle Scholar
  13. 13.
    De Jong D, Prins FA, Mason DY, et al. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 1994;54:256–60.PubMedGoogle Scholar
  14. 14.
    Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Muscarella DE, O'Brien KA, Lemley AT, et al. Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. Toxicol Sci. 2003;74:66–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Hirsch T, Marzo I, Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep. 1997;17:67–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Ferry A, Jaillon P, Lecocq B, et al. Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers. Fundam Clin Pharmacol. 1989;3:383–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Ansseau M, von Frenckell R, Cerfontaine JL, et al. Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry. 1991;24:8–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Takai N, Ueda T, Nishida M, et al. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMedGoogle Scholar
  21. 21.
    Rimon G, Bazenet CE, Philpott KL, et al. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen Y, Kramer DL, Diegelman P, et al. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437–44.PubMedGoogle Scholar
  23. 23.
    Takai N, Ueda T, Nasu K, et al. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Johnson D, Walker C. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312.CrossRefPubMedGoogle Scholar
  25. 25.
    Sherr C. G1 phase progression: cycling on cue. Cell. 1994;79:551–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Kyushima N, Watanabe J, Hata H, et al. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128:307–12.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Noriyuki Takai
    • 1
  • Naoko Kira
    • 1
  • Terukazu Ishii
    • 1
  • Toshie Yoshida
    • 1
  • Masakazu Nishida
    • 1
  • Yoshihiro Nishida
    • 1
  • Kaei Nasu
    • 1
  • Masayuki Takano
    • 1
  • Haruna Midori
    • 1
  • Satoko Koga
    • 1
  • Hisashi Narahara
    • 1
  1. 1.Department of Obstetrics and Gynecology, Faculty of MedicineOita UniversityYufu-shiJapan

Personalised recommendations